Format

Send to

Choose Destination
J Nucl Med. 2014 Apr;55(4):647-9. doi: 10.2967/jnumed.113.132340. Epub 2014 Mar 6.

Acute administration of haloperidol does not influence 123I-FP-CIT binding to the dopamine transporter.

Author information

1
Department of Nuclear Medicine, University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands; and.

Abstract

A recent (123)I-FP-CIT ((123)-I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane) SPECT study on rats suggested that a single 1 mg/kg dose of the antipsychotic haloperidol induces enough dopamine release to compete with (123)I-FP-CIT for binding to the dopamine transporter. Taking into account the far-reaching consequences of this proposition, we were interested in testing whether we could reproduce this finding using storage phosphor imaging.

METHODS:

Twenty rats were pretreated with saline or haloperidol (1 mg/kg of body weight) and then injected with (123)I-FP-CIT. Two hours after (123)I-FP-CIT injection, the rats were sacrificed and binding in the striatum, nucleus accumbens, and cerebellum (nonspecific binding) was measured.

RESULTS:

In contrast to the earlier SPECT finding, acute administration of haloperidol did not induce a significant change in (123)I-FP-CIT binding ratios in the striatum and nucleus accumbens.

CONCLUSION:

Changes in synaptic dopamine due to acute haloperidol administration were not detectable with (123)I-FP-CIT.

KEYWORDS:

antipsychotics; dopamine release; dopamine transporter; haloperidol; rats

PMID:
24604911
DOI:
10.2967/jnumed.113.132340
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center